{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:18:30Z","timestamp":1767853110017,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ijid.2021.10.030","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T09:39:16Z","timestamp":1634895556000},"page":"165-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1\/2 trial"],"prefix":"10.1016","volume":"114","author":[{"given":"Michiko","family":"Asano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.10.030_bib0001","doi-asserted-by":"crossref","first-page":"e02107","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate","volume":"58","author":"Addetia","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2021.10.030_bib0002","unstructured":"AstraZeneca. AZD1222 US Phase III primary analysis confirms safety and efficacy. AstraZeneca; 2021. Available at: https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html (accessed 9 July 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.10.030_bib0004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2021.10.030_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: vulnerability, immunity and intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.ijid.2021.10.030_bib0006","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abc5343","article-title":"Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques","volume":"369","author":"Deng","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijid.2021.10.030_bib0007","unstructured":"European Medicines Agency. Draft guideline on clinical evaluation of vaccines \u2013 Revision 1. EMA; 2018. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-evaluation-vaccines-revision-1_en.pdf (accessed 28 October 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0008","unstructured":"European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. EMA; 2021a. Available at: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (accessed 21 May 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0009","unstructured":"European Medicines Agency. Vaxzevria (previously covid-19 vaccine AstraZeneca). EMA; 2021b. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria-previously-covid-19-vaccine-astrazeneca (accessed 25 May 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2021.10.030_bib0011","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.10.030_bib0012","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0013","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0014","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamainternmed.2021.0366","article-title":"Association of SARS-CoV-2 seropositive antibody test with risk of future infection","volume":"181","author":"Harvey","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijid.2021.10.030_bib0016","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(21)00782-0","article-title":"Correlates of protection from SARS-CoV-2 infection","volume":"397","author":"Krammer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0017","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.10.030_bib0018","unstructured":"Medicines and Healthcare Products Regulatory Agency. Statement on AstraZeneca COVID-19 vaccine following JCVI update. MHRA; 2021a. Available at: https:\/\/www.gov.uk\/government\/news\/statement-on-astrazeneca-covid-19-vaccine-following-jcvi-update (accessed 3 June 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0019","unstructured":"Medicines and Healthcare Products Regulatory Agency. Summary of Product Characteristics for Vaxzevria. MHRA 2021b https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca\/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca (accessed 25 November, 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0020","unstructured":"National Institute of Population and Social Security Research. Trend of COVID-19 cases and deaths in Japan (as of 10 May 21). National Institute of Population and Social Security Research; 2021. Available at: http:\/\/www.ipss.go.jp\/projects\/j\/choju\/covid19\/index-en.asp (accessed 13 May 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0022","doi-asserted-by":"crossref","first-page":"e13520","DOI":"10.1111\/eci.13520","article-title":"SARS-CoV-2 re-infection risk in Austria","volume":"51","author":"Pilz","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijid.2021.10.030_bib0023","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2021.10.030_bib0024","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.10.030_bib0021","unstructured":"Pharmaceuticals and Medical Devices Agency. Vaxzevria review report (English). PMDA; 2021. Available at: https:\/\/www.pmda.go.jp\/files\/000242500.pdf (accessed 22 June 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0026","unstructured":"Statistics Bureau of Japan. Statistical handbook of Japan 2020. Chapter 2: Population. Statistics Bureau of Japan; 2021. Available at: https:\/\/www.stat.go.jp\/english\/data\/handbook\/pdf\/2020all.pdf#page=23 (accessed 1 April 2021)."},{"key":"10.1016\/j.ijid.2021.10.030_bib0027","doi-asserted-by":"crossref","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","article-title":"A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques","volume":"6","author":"van Doremalen","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.ijid.2021.10.030_bib0028","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2021.10.030_bib0029","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2021.10.030_bib0031","first-page":"ciaa721","article-title":"Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2021.10.030_sbref0032","series-title":"Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine","year":"2021"},{"key":"10.1016\/j.ijid.2021.10.030_bib0033","series-title":"The COVID-19 candidate vaccine landscape","year":"2020"},{"key":"10.1016\/j.ijid.2021.10.030_bib0034","series-title":"WHO coronavirus disease (COVID-19) dashboard","year":"2020"},{"key":"10.1016\/j.ijid.2021.10.030_bib0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2021.10.030_bib0036","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221008183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:05:28Z","timestamp":1761120328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221008183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"alternative-id":["S1201971221008183"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.030","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1\/2 trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}